Healthpoint, DFB To Pay $48M To End FCA Drug Suit

Law360, New York (December 6, 2012, 4:03 PM EST) -- Healthpoint Ltd. and DFB Pharmaceuticals Inc. will pay $48 million as part of a settlement agreement that ended allegations that Healthpoint submitted false claims to Medicare and Medicaid for an unapproved prescription skin ointment, the U.S. Department of Justice said Thursday.

The DOJ said that in January 2011, it intervened in a False Claims Act case against Texas-based Healthpoint, a subsidiary of DFB, alleging the company launched Xenaderm, a prescription skin ointment used for treating nursing home patients' bedsores, without any approval from the U.S. Food...
To view the full article, register now.



Case Information

Case Title

United States, ex rel v. Actavis Mid-Atlantic, et al

Case Number




Nature of Suit

Other Statutory Actions


Rya W. Zobel

Date Filed

August 29, 2002

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.